DEALS: Qiagen buys key assets


Qiagen buys key assets


DEALS

WHO

WITH

WHAT

SCOOP

Altana

Eckhart

$768 million buyout

Once the deal is complete, Altana will add Eckhart's chemicals and pigments unit to its chemicals division and spin the venture off as a separate company.

Qiagen

SuNyx

asset buyout

Qiagen buys technology that examines sample preparation by leveraging unique, nanotechnology-based surface structures.

Qiagen

LumiCyte

asset buyout

LumiCyte has been developing capability that dramatically increases the limits of detection achievable through mass spectroscopy.

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.